+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2026-2032- Product Image
Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2026-2032- Product Image
Sale

Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829907
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Disease Diagnostic Market is projected to reach USD 29.41 Billion in 2026. It is expected to continue growing at a CAGR of 8.93%, reaching USD 49.28 Billion by 2032.

Infectious disease diagnostics form the clinical and public health backbone for detecting, confirming, monitoring, and controlling communicable diseases. The market spans molecular diagnostics, immunoassays, rapid antigen tests, culture-based microbiology, antimicrobial susceptibility testing, sequencing, syndromic panels, and point-of-care testing used across hospitals, reference laboratories, public health agencies, and decentralized care settings.

Demand remains anchored in measurable disease burden. WHO reported 10.8 million tuberculosis cases in 2023 and an estimated 263 million malaria cases in 2023; UNAIDS reported nearly 40 million people living with HIV in 2024; and antimicrobial resistance was associated with 1.27 million attributable deaths in 2019. These realities continue to prioritize accurate, fast, and scalable infectious disease testing that supports timely treatment, outbreak containment, and evidence-based surveillance.

Transformative Shifts in Infectious Disease Diagnostics

The infectious disease diagnostic landscape is shifting from centralized, single-pathogen testing toward faster, multiplexed, and decentralized models. PCR and other nucleic acid amplification tests remain essential for high-sensitivity detection, while rapid antigen, lateral flow, and near-patient molecular platforms are expanding access where turnaround time directly affects isolation, treatment, antimicrobial selection, and outbreak control.

Public health surveillance is also becoming more integrated with clinical diagnostics. Wastewater monitoring, genomic sequencing, antimicrobial susceptibility testing, and electronic laboratory reporting are increasingly linked to preparedness programs. At the same time, IVDR implementation in Europe, FDA oversight in the United States, and quality requirements for laboratory-developed tests are raising expectations for analytical validation, traceability, clinical evidence, and post-market performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming an enabling layer across infectious disease diagnostics rather than a standalone replacement for laboratory science. AI-supported image analysis can assist digital microscopy, colony recognition, and radiology triage, while machine learning models can prioritize sepsis risk, optimize antimicrobial stewardship, flag abnormal laboratory patterns, and support outbreak forecasting when connected to validated clinical and epidemiological data.

The cumulative impact is faster decision support, improved laboratory workflow, and stronger population-level surveillance. However, adoption depends on transparent validation, representative datasets, cybersecurity, interoperability, bias monitoring, and clinician oversight. Industry leaders that combine AI with regulatory-grade evidence, laboratory information systems, and explainable outputs will be better positioned to convert automation into trusted diagnostic value.

Regional Dynamics Across Infectious Disease Diagnostics

Asia-Pacific is a high-priority infectious disease diagnostics region due to large population scale, persistent TB, dengue, hepatitis, malaria, and respiratory infection burden, and expanding molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN countries. WHO has consistently identified South-East Asia and the Western Pacific as central regions for tuberculosis and arboviral disease surveillance, supporting continued demand for rapid diagnostic tests, molecular assays, and public health laboratory strengthening.

North America remains a technology leader, supported by CLIA-certified laboratories, FDA-cleared diagnostic platforms, CDC surveillance networks, strong laboratory quality systems, and rapid uptake of syndromic and molecular testing for respiratory pathogens, sexually transmitted infections, sepsis, and healthcare-associated infections. Latin America faces recurring dengue, Zika, chikungunya, TB, HIV, and respiratory disease pressures, driving demand for affordable rapid tests, decentralized sample collection, and regional reference laboratory capacity.

Europe is shaped by strong public health systems, antimicrobial resistance programs, cross-border disease surveillance, and EU IVDR compliance, with laboratories prioritizing validated assays, traceability, and quality management. The Middle East is investing in laboratory modernization and preparedness linked to international travel, migration, and mass-gathering risks, while Africa remains central to global diagnostic access priorities for HIV, TB, malaria, cholera, viral hemorrhagic fevers, and outbreak-prone pathogens.

Strategic Group Insights for Infectious Disease Testing

ASEAN demand is influenced by dengue seasonality, TB control, respiratory infections, cross-border mobility, and the need for scalable point-of-care diagnostics across island, rural, and high-density urban health systems. The region’s public health priorities support rapid antigen testing, molecular confirmation, laboratory networking, and digital reporting for diseases with epidemic potential.

GCC countries are advancing laboratory automation, molecular diagnostics, and biosurveillance through hospital investment, public health modernization, and preparedness for travel-associated infections and mass-gathering events. The European Union is defined by harmonized regulatory expectations under IVDR, ECDC-led surveillance coordination, antimicrobial resistance strategies, and laboratory quality requirements that favor clinically validated and traceable diagnostic solutions.

BRICS countries combine high infectious disease burden with expanding diagnostic infrastructure, domestic manufacturing capacity, and public health programs focused on TB, HIV, hepatitis, malaria, respiratory infections, and antimicrobial resistance. G7 markets lead in R&D funding, reimbursement depth, pandemic preparedness, genomic surveillance, and advanced laboratory automation, while NATO members increasingly view infectious disease diagnostics as part of biosecurity, resilience, and civilian-military health preparedness.

Country-Level Insights Shaping Diagnostic Demand

The United States leads in molecular diagnostics adoption, public health reporting, laboratory-developed testing capacity, and FDA-regulated innovation, while Canada emphasizes coordinated provincial laboratory networks, antimicrobial resistance monitoring, and respiratory virus surveillance. Mexico and Brazil show strong demand for affordable infectious disease testing across dengue, TB, HIV, hepatitis, and respiratory pathogens, with Brazil also benefiting from established public health institutes, surveillance experience, and local production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by public reimbursement, hospital laboratory consolidation, antimicrobial resistance programs, respiratory surveillance, and IVDR transition planning, while Russia maintains demand across TB, viral hepatitis, HIV, and respiratory testing. These countries continue to prioritize diagnostic quality, laboratory automation, and validated molecular and immunoassay platforms aligned with national health systems.

China and India represent large-scale diagnostic priorities due to population size, domestic manufacturing, expanding hospital networks, and significant infectious disease burden, including TB, viral hepatitis, dengue, respiratory infections, and antimicrobial resistance concerns. Japan, Australia, and South Korea are advanced diagnostic markets with strong quality systems, aging populations, high uptake of automated molecular and syndromic testing, and active surveillance for influenza, COVID-19, antimicrobial resistance, and emerging pathogens.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, high-throughput molecular platforms, rapid point-of-care formats, antimicrobial susceptibility tools, and multiplex panels that address respiratory infections, sexually transmitted infections, sepsis, TB, HIV, hepatitis, malaria, dengue, and antimicrobial resistance. Product strategies should align with clinical workflows, reimbursement evidence, sample-to-answer usability, quality control, connectivity, and total cost of ownership.

Organizations should also invest in regional manufacturing resilience, regulatory readiness, and data connectivity. Partnerships with public health agencies, hospitals, non-governmental organizations, and reference laboratories can accelerate adoption in underserved regions. AI capabilities should be embedded only where they improve accuracy, turnaround time, workflow efficiency, antimicrobial stewardship, or surveillance value and are supported by auditable clinical evidence.

Research Methodology

The research methodology is built from verified secondary research and data triangulation across public health, regulatory, and scientific sources, including WHO, CDC, ECDC, FDA, UNAIDS, national health agencies, peer-reviewed literature, and major infectious disease surveillance reports. Disease burden, regulatory direction, diagnostic workflow, technology adoption patterns, and public health priorities were assessed to identify durable industry drivers.

The methodology emphasizes evidence-based interpretation rather than speculative forecasting. Insights were validated through cross-source comparison, with attention to disease prevalence, diagnostic performance, laboratory infrastructure, regulatory controls, regional healthcare capacity, procurement dynamics, and surveillance needs. Conclusions were framed to support strategic planning for diagnostic manufacturers, laboratories, healthcare providers, investors, public health organizations, and policymakers.

Conclusion

Infectious disease diagnostics are moving into a new era defined by speed, decentralization, genomic intelligence, antimicrobial resistance monitoring, and connected surveillance. Persistent global burdens from TB, malaria, HIV, respiratory viruses, dengue, hepatitis, healthcare-associated infections, and drug-resistant pathogens ensure that accurate testing remains essential to both individual care and public health security.

The strongest industry positions will belong to organizations that combine scientific validity, regulatory compliance, scalable access, workflow integration, and digital connectivity. As healthcare systems prepare for endemic threats and future outbreaks, diagnostics will continue to serve as the first line of detection, the guide for targeted treatment, and the foundation for evidence-based infectious disease control.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infectious Disease Diagnostic Market, by Product
7.1. Instruments
7.1.1. Immunoassay Analyzers
7.1.2. Mass Spectrometers
7.1.3. Microarrays
7.1.4. PCR Systems
7.2. Reagents & Kits
7.2.1. Antigen Detection Kits
7.2.2. ELISA Kits
7.2.3. Immunoassay Kits
7.2.4. PCR Kits
7.3. Software
8. Infectious Disease Diagnostic Market, by Sample Type
8.1. Blood
8.2. Stool
8.3. Swab
8.3.1. Nasal
8.3.2. Rectal
8.3.3. Throat
8.4. Urine
9. Infectious Disease Diagnostic Market, by Testing Type
9.1. Laboratory Testing
9.2. PoC Testing
10. Infectious Disease Diagnostic Market, by Pathogen Type
10.1. Bacterial
10.2. Fungal
10.3. Parasitic
10.4. Viral
10.4.1. Hepatitis
10.4.2. HIV
10.4.3. Influenza
11. Infectious Disease Diagnostic Market, by Disease Type
11.1. Bacterial Infectious Diseases
11.1.1. Meningitis
11.1.2. Pneumonia
11.1.3. Tuberculosis
11.2. Fungal Infections
11.2.1. Aspergillosis
11.2.2. Candidiasis
11.2.3. Cryptococcosis
11.3. Parasitic Infections
11.3.1. Leishmaniasis
11.3.2. Malaria
11.3.3. Schistosomiasis
11.4. Vector-borne Infections
11.4.1. Dengue Fever
11.4.2. Lyme Disease
11.4.3. Zika Virus
11.5. Viral Infectious Diseases
11.5.1. Hepatitis (A, B, C)
11.5.2. Hepatitis B & C
11.5.3. HIV/AIDS
11.5.4. Influenza
12. Infectious Disease Diagnostic Market, by End-User
12.1. Academic & Research Institutes
12.2. Diagnostic Laboratories
12.3. Hospitals & Clinics
13. Asia-Pacific Infectious Disease Diagnostic Market
14. Europe Infectious Disease Diagnostic Market
15. North America Infectious Disease Diagnostic Market
16. Africa Infectious Disease Diagnostic Market
17. Latin America Infectious Disease Diagnostic Market
18. Middle East Infectious Disease Diagnostic Market
19. NATO Infectious Disease Diagnostic Market
20. G7 Infectious Disease Diagnostic Market
21. European Union Infectious Disease Diagnostic Market
22. BRICS Infectious Disease Diagnostic Market
23. ASEAN Infectious Disease Diagnostic Market
24. GCC Infectious Disease Diagnostic Market
25. United States Infectious Disease Diagnostic Market
26. China Infectious Disease Diagnostic Market
27. Germany Infectious Disease Diagnostic Market
28. Japan Infectious Disease Diagnostic Market
29. India Infectious Disease Diagnostic Market
30. United Kingdom Infectious Disease Diagnostic Market
31. France Infectious Disease Diagnostic Market
32. Italy Infectious Disease Diagnostic Market
33. Canada Infectious Disease Diagnostic Market
34. Australia Infectious Disease Diagnostic Market
35. Russia Infectious Disease Diagnostic Market
36. Brazil Infectious Disease Diagnostic Market
37. South Korea Infectious Disease Diagnostic Market
38. Mexico Infectious Disease Diagnostic Market
39. Spain Infectious Disease Diagnostic Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Adaptive Biotechnologies Corporation
41.3. Agilent Technologies, Inc.
41.4. Becton, Dickinson and Company
41.5. Bio-Rad Laboratories, Inc.
41.6. Bio-Techne Corporation
41.7. bioMérieux SA
41.8. Boston Scientific Corporation
41.9. Bruker Corporation
41.10. Cardinal Health Inc.
41.11. Danaher Corporation
41.12. F. Hoffmann-La Roche Ltd.
41.13. GE HealthCare Technologies Inc.
41.14. Grifols, S.A.
41.15. Hologic Inc.
41.16. Illumina, Inc.
41.17. Johnson & Johnson Services Inc.
41.18. Konica Minolta, Inc.
41.19. Koninklijke Philips N.V.
41.20. MedMira Inc.
41.21. Medtronic PLC
41.22. Merck KGaA
41.23. Olympus Corporation
41.24. Perkin Elmer, Inc.
41.25. Pfizer Inc.
41.26. Qiagen N.V.
41.27. Quest Diagnostics Incorporated
41.28. Siemens Healthineers AG
41.29. Sysmex Corporation
41.30. Thermo Fisher Scientific, Inc.
41.31. Trivitron Healthcare
List of Figures
FIGURE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. JAPAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. RUSSIA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PCR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PCR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PCR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ELISA KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ELISA KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ELISA KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PCR KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PCR KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PCR KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL STOOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL STOOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL THROAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL THROAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL THROAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL POC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL POC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL POC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ASPERGILLOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ASPERGILLOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ASPERGILLOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL CANDIDIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL CANDIDIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL CANDIDIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL LEISHMANIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL LEISHMANIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL LEISHMANIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL MALARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL DENGUE FEVER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL DENGUE FEVER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL DENGUE FEVER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL LYME DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL LYME DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL LYME DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL ZIKA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL ZIKA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL ZIKA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL HEPATITIS B & C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL HEPATITIS B & C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL HEPATITIS B & C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL HIV/AIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL HIV/AIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL HIV/AIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 183. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 184. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 185. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 188. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 189. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 192. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 193. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 194. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 195. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 196. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 197. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 198. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 213. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 214. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 215. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 216. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 217. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 219. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 220. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 221. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 222. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 223. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 224. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 225. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 226. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 227. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 228. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 229. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 230. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 233. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 234. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 235. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 236. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 237. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 238. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 239. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 240. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 241. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 242. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 243. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 244. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 245. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 246. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 247. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 259. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 260. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 261. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 262. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 263. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 264. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 265. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 266. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 267. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 268. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 269. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 270. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 271. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 272. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 273. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 274. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 275. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 276. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 277. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 278. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 279. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 280. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 281. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 282. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 283. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 284. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 285. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 286. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 287. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 288. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 289. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 290. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 291. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 292. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 293. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 294. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 311. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 312. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 313. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 314. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 315. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 316. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 317. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 318. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 319. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 320. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 321. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 322. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 323. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 324. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 325. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 326. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 327. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 328. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 329. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 330. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 331. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 332. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 333. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 334. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 335. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
TABLE 336. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 337. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 338. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
TABLE 339. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
TABLE 340. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
TABLE 341. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 342. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 343. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 344. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
TABLE 345. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
TABLE 346. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
TABLE 347. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 348. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
TABLE 349. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
TABLE 350. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
TABLE 351. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SI

Companies Mentioned

The companies featured in this Infectious Disease Diagnostic market report include:
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux SA
  • Boston Scientific Corporation
  • Bruker Corporation
  • Cardinal Health Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Grifols, S.A.
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • MedMira Inc.
  • Medtronic PLC
  • Merck KGaA
  • Olympus Corporation
  • Perkin Elmer, Inc.
  • Pfizer Inc.
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare

Table Information

Report AttributeDetails
No. of Pages190
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 29.41 Billion
Forecasted Market Value ( USD ) by 2032 $ 49.28 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User - Product Image

North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

  • Report
  • 115 Pages
  • North America
From
Asia Pacific Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User - Product Image

Asia Pacific Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

  • Report
  • 136 Pages
  • Asia Pacific
From
Infectious Disease Diagnostics - Global Strategic Business Report - Product Image

Infectious Disease Diagnostics - Global Strategic Business Report

  • Report
  • 756 Pages
  • Global
From
Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032 - Product Image

Healthcare-associated Infectious Disease Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032 - Product Image

Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From

About the Infectious Disease Testing Market

The Infectious Disease Testing market is a sector of the healthcare industry that focuses on the diagnosis and treatment of infectious diseases. It includes a range of tests, such as blood tests, urine tests, and swab tests, to detect the presence of a pathogen. These tests are used to diagnose a wide range of infectious diseases, including HIV, hepatitis, and tuberculosis. The Infectious Disease Testing market is driven by the increasing prevalence of infectious diseases, the growing demand for rapid and accurate diagnosis, and the development of new technologies. Companies in this market are developing innovative tests and technologies to improve the accuracy and speed of diagnosis. Some of the major companies in the Infectious Disease Testing market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. These companies are investing in research and development to develop new tests and technologies to improve the accuracy and speed of diagnosis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.